ED as a Cardiovascular Warning Sign: the labs that confirm it

Most men (and most clinicians, honestly) treat erectile dysfunction as a bedroom problem. It usually isn't. ED is one of the earliest visible symptoms of endothelial dysfunction — the same process that eventually narrows coronary arteries. If you understand that, the workup changes completely.

This article walks through why ED tends to precede cardiovascular disease by years, which labs actually confirm the vascular picture, and how to tell whether your ED is a plumbing issue, a hormonal issue, or the increasingly common overlap of both.

Why the penis is the canary in the coal mine

The cavernosal arteries that fill the penis are roughly 1–2 mm in diameter. The coronary arteries are 3–4 mm. The carotids are 5–7 mm. When systemic endothelial dysfunction starts — the inner lining of arteries losing its ability to produce nitric oxide and dilate on demand — the smallest vessels feel it first.

That's not a metaphor. In a landmark analysis from the Prostate Cancer Prevention Trial, men who developed ED had a significantly higher risk of subsequent cardiovascular events, and ED preceded coronary artery disease diagnosis by an average of 3–5 years (Thompson et al., JAMA 2005). Later meta-analyses have confirmed a ~44% increased risk of cardiovascular events and ~25% increased all-cause mortality in men with ED versus matched controls (Dong et al., J Am Coll Cardiol 2011).

Translation: new-onset ED in a man in his 40s or 50s is a cardiovascular screening event, not just a sexual health complaint.

What's actually going wrong — in plain English

An erection is a vascular event driven by nitric oxide (NO). Sexual stimulation triggers endothelial and neuronal NO release, which relaxes smooth muscle in the cavernosal arteries, blood floods in, and venous outflow gets compressed. The whole cascade depends on a healthy endothelium.

Three things damage that endothelium:

• Metabolic: high glucose, high insulin, high ApoB particle count, oxidized LDL.
• Inflammatory: elevated hs-CRP, visceral adiposity, poor sleep.
• Hormonal: low testosterone reduces NO synthase expression and blunts the whole pathway.

Most men over 45 with ED have some combination of all three. Which is why treating ED with a PDE5 inhibitor alone — while often effective symptomatically — can miss the actual disease trajectory underneath.

The labs that separate vascular ED from hormonal ED

If you're going to run bloodwork for ED, these are the markers worth having. Not all of these are on a standard primary care panel.

Cardiometabolic markers

• ApoB. Better than LDL-C for atherosclerotic risk because it counts particles, not cholesterol content. Target for men with any vascular symptom is generally <80 mg/dL, and <60 mg/dL if established disease (per ESC/EAS 2019 guidelines).
• Lipoprotein(a). Genetic, measured once in a lifetime. Elevated Lp(a) (>50 mg/dL or >125 nmol/L) is an independent driver of endothelial dysfunction.
• hs-CRP. Inflammation marker. >2.0 mg/L suggests meaningful systemic inflammation; >3.0 mg/L is high cardiovascular risk (AHA cut points).
• HbA1c and fasting insulin. ED is often the first noticeable symptom of insulin resistance. An HbA1c of 5.7–6.4% (prediabetes) doubles ED risk versus normoglycemic men.
• Blood pressure. Not a lab, but the single most important number. Uncontrolled hypertension is the most common vascular cause of ED.

Hormonal markers

• Total and free testosterone. Draw in the morning (before 10 AM), ideally fasted, ideally twice on separate days before making decisions. Symptomatic low T is generally defined as total testosterone <300 ng/dL with symptoms (AUA 2018 guideline).
• SHBG. Governs how much testosterone is bioavailable. High SHBG can make a "normal" total T functionally low.
• Estradiol (sensitive assay). Both very low and very high estradiol contribute to erectile and libido problems.
• Prolactin. Elevated prolactin suppresses libido and erectile function; worth ruling out.
• TSH. Hypothyroidism is a quiet contributor to ED and low libido.

{callout: The single most important takeaway} New-onset ED in a man under 60 should trigger a cardiovascular workup — ApoB, hs-CRP, HbA1c, and blood pressure — before it's treated as a purely sexual issue.

How to read the pattern — what your labs are telling you

A few common patterns we see when men run a full workup:

Pattern 1: The vascular story. Testosterone is normal. ApoB is elevated (say, 110 mg/dL). hs-CRP is 2.5. HbA1c is 5.9. Blood pressure runs 138/88. This man's ED is a small-vessel disease signal. PDE5 inhibitors will likely work, but the real intervention is lipid management, blood pressure control, and metabolic work. His ED is a gift — an early warning most men don't get.

Pattern 2: The hormonal story. Total testosterone is 240 ng/dL on two morning draws, free testosterone is low, SHBG is normal, LH is low-normal (suggesting secondary hypogonadism). Lipids and inflammation are clean. Here, the conversation is about whether testosterone therapy makes sense — with the understanding that TRT is a long-term commitment and benefits from clinician oversight.

Pattern 3: The overlap (most common after 45). Testosterone is 320 ng/dL — technically "normal" but low for his age and symptoms. ApoB is 95. HbA1c is 5.8. hs-CRP is 3.1. This man has both metabolic disease and borderline hypogonadism, and they're feeding each other. Low T worsens visceral fat, which worsens insulin resistance, which lowers T further. Addressing one without the other tends to disappoint.

What a thorough ED workup looks like

If you're bringing ED to a clinician, a thorough workup would typically include:

1. A symptom timeline (gradual vs. sudden; nocturnal erections preserved or not — nocturnal erections argue against a purely vascular cause). 2. Blood pressure and waist circumference. 3. A cardiometabolic panel: ApoB, full lipid panel, Lp(a) once, hs-CRP, HbA1c, fasting glucose, fasting insulin. 4. A hormone panel: morning total and free testosterone (twice), SHBG, LH, FSH, estradiol (sensitive), prolactin, TSH. 5. A conversation about sleep (untreated sleep apnea drops testosterone and destroys endothelial function), alcohol, medications (SSRIs, beta-blockers, finasteride), and mental health.

If you choose to run bloodwork through DirectCare AI, these are the markers we prioritize first for ED evaluation. If you already have recent labs, bring them — there's no point repeating what you have.

Treatment implications: treat the symptom, treat the cause

PDE5 inhibitors (sildenafil, tadalafil) are effective and reasonably safe for most men. They work by amplifying the NO/cGMP signal — but they can't amplify a signal that isn't there. That's why men with severe endothelial dysfunction or very low testosterone sometimes respond poorly to PDE5s alone.

The strongest evidence-based interventions for ED that also improve cardiovascular outcomes:

• Aerobic exercise, 150+ minutes/week. Improves endothelial function within weeks. Multiple RCTs show meaningful ED improvement.
• Weight loss of 5–10% in men with metabolic syndrome improves erectile function scores (Esposito et al., JAMA 2004).
• Lipid and blood pressure control. Statins have mixed direct effects on ED but reduce the underlying disease.
• Testosterone therapy when clinically indicated — improves libido reliably, improves erectile function modestly, and works synergistically with PDE5s in hypogonadal men.

ED that responds to a pill is still ED. The pill treats the erection; it doesn't treat the artery.

The bottom line

Erectile dysfunction is worth taking seriously not because sex is the point, but because the vessels are. A man who acts on new-onset ED in his 40s or early 50s — runs the right labs, addresses the metabolic and hormonal drivers, and doesn't just paper over it with a prescription — is a man who has been handed a rare early warning about his cardiovascular future.

That's the real value of the workup. The erection is downstream. The arteries are the story.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.